At a glance
- Omiganan is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 53 publications mentioning it, including 5 randomized controlled trials and 5 animal-only studies.
- ClinicalTrials.gov lists 18 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- From computational screening to in vitro validation: exploring antimicrobial peptides against Pseudomonas aeruginosa.
- Fluoroalkylated antimicrobial peptides enables cytosolic delivery and eradication of intracellular Staphylococcus aureus.
- Peptide-based antibiotics: structure-driven strategies to tackle toxicity and resistance of antimicrobial peptides.
- Treatment Interventions for Usual-Type Vulvar Intraepithelial Neoplasia: A Systematic Review and Meta-analysis.
- A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy.
- The Study of Antistaphylococcal Potential of Omiganan and Retro-Omiganan Under Flow Conditions.
- Omiganan-Based Synthetic Antimicrobial Peptides for the Healthcare of Infectious Endophthalmitis.
- Antibacterial and Hemolytic Activity of Antimicrobial Hydrogels Utilizing Immobilized Antimicrobial Peptides.
- An infection-microenvironment-targeted and responsive peptide-drug nanosystem for sepsis emergency by suppressing infection and inflammation.
- Ceragenins exhibit bactericidal properties that are independent of the ionic strength in the environment mimicking cystic fibrosis sputum.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 18
- Active
- 0
- With posted results
- 5
Conditions studied
Show 8 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris | Completed | Phase 2 | Apr 2014 |
| A 21 Day Pharmacokinetics Study in Papulopustular Rosacea | Completed | Phase 1 | Jan 2014 |
| A Twelve Week Safety and Efficacy Study in Rosacea | Completed | Phase 2 | Mar 2013 |
| Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects | Completed | Phase 3 | May 2008 |
| Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters | Completed | Phase 3 | Aug 2005 |
| Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne | Completed | Phase 2 | Jan 2003 |
| Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne | Completed | Phase 2 | Oct 2000 |
| Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections | Completed | Phase 3 | Sep 2000 |
All 18 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.